



(11) **EP 1 757 302 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1)

Bibliography INID code(s) 71, 72

(51) Int Cl.:

A61K 38/00 (2006.01) **A61K 48/00** (2006.01)

A61P 3/00 (2006.01) **A61P 3/10** (2006.01)

A61P 9/00 (2006.01) **C12N 5/10** (2006.01)

C12Q 1/02 (2006.01) **G01N 33/15** (2006.01)

(48) Corrigendum issued on:

12.12.2007 Bulletin 2007/50

(86) International application number:

PCT/JP2005/006357

(43) Date of publication:

28.02.2007 Bulletin 2007/09

(87) International publication number:

WO 2005/094866 (13.10.2005 Gazette 2005/41)

(21) Application number: **05727594.3**

(22) Date of filing: **31.03.2005**

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR**

• **YAMAUCHI, Toshimasa**

Tokyo 113-0024 (JP)

• **KITAJIMA, Shoko**

c/o Mitsubishi Pharma Corporation

Tokyo 103-8405 (JP)

• **ITO, Yusuke**

c/o Biological Research Laboratories

Nissan Chemical Industries, Ltd.

Minamisaitama-gun,

Saitama 349-0294 (JP)

(30) Priority: **31.03.2004 US 557708 P**

(71) Applicants:

• **TOUDAI TLO, Ltd.**

Tokyo 113-0033 (JP)

• **Nissan Chemical Industries, Ltd.**

Chiyoda-ku,

Tokyo 101-0054 (JP)

(74) Representative: **Dehmel, Albrecht**

Dehmel & Bettenhausen

Patentanwälte,

Herzogspitalstrasse 11

80331 München (DE)

(72) Inventors:

• **KADOWAKI, Takashi**

Tokyo 113-0034 (JP)

(54) **ADIPONECTIN EXPRESSION INDUCER AND UTILIZATION OF THE SAME**

(57) The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents.

KLF9, which can bind to the 32-bp fragment of position -188 to position -157 from the adiponectin expres-

sion start site, was demonstrated to enhance adiponectin promoter activity.

Therefore, the present invention uses KLF9 as an adiponectin expression-inducing agent, and suggests that KLF9 replenishment therapy is useful for preventing and/or treating obesity or obesity-related diseases including metabolic diseases such as insulin resistance and type II diabetes, and cardiovascular diseases.

FIG. 1

